



REGISTER TODAY
Limited seats available

Unfolding the Subject Matter

The understanding of Multiple Sclerosis (MS) as a dynamic and multifactorial disease continues to advance, integrating new perspectives from neuroimmunology, neurodegeneration, and biomarker research.

Professor Hartung will explore how microglial activation contributes to chronic neuroinflammation and axonal injury, emphasizing its potential as a therapeutic target. He will also address how emerging Bruton's Tyrosine Kinase inhibitors (BTKis) may modulate both peripheral immune responses and CNS-compartmentalized inflammation.

Professor Zakaria will focus on the identification of prognostic factors and early indicators that guide personalized therapeutic strategies in treatment-naïve patients, highlighting how early intervention may influence long-term outcomes.

Professor Oreja-Guevara will discuss evolving approaches to detect and monitor disease progression beyond relapses and MRI activity, including clinical, imaging, and digital biomarkers that capture subtle disability worsening.

The session will conclude with a panel discussion led by Professor Yamout, integrating these expert perspectives to define how the latest advances in pathophysiology, biomarkers, and therapeutic strategies can be translated into daily clinical practice and individualized patient management.

Target Audience

- Specialists
- Neurologists
- Practitioners
- Researchers in the field of MS

Registration

Registration is **complimentary and mandatory** and can be arranged via the online registration module available on the webpage.

Agenda

13:30-14:00 Registration

14:00-15:00 **Practical Strategies for Early Treatment and Detecting Progression in MS**
Chairs: B. Yamout (AE)

14:00-14:05 Welcome

14:05-14:20 The Role of Microglia in Multiple Sclerosis: Implications for Treatment with Bruton's Tyrosine Kinase Inhibitors

14:20-14:35 Prognostic Factors for Evaluation of MS Therapy in Treatment Naïve Patients

14:35-14:50 How to Detect Progression in Multiple Sclerosis

14:50-15:00 Q&A and Panel Discussion

B. Yamout (AE) &
C. Oreja-Guevara (ES)

H.P. Hartung (DE)

M. Zakaria (EG)

C. Oreja-Guevara (ES)

*All faculty, facilitated by
B. Yamout (AE)*

Faculty



Prof. Bassem I. Yamout
Neurology Institute Director
Harley Street Medical Centre
Abu Dhabi, United Arab Emirates



Prof. Hans-Peter Hartung
Professor and Honorary
Professor
Heinrich Heine Universität &
University of Sydney
Düsseldorf, Germany



Prof. Magd Zakaria
Professor of Neurology
Ain Shams University
Cairo, Egypt



Prof. Celia Oreja-Guevara
Vice Chair of Neurology
University Hospital San Carlos
Madrid, Spain

What are the key takeaways from this Symposium?

By attending this symposium you will:

- Discover the pivotal role of microglia in multiple sclerosis (MS) and how their interaction with the immune system shapes disease activity and progression. Learn how Bruton's Tyrosine Kinase inhibitors (BTKi) are emerging as a promising treatment approach, offering new possibilities for personalized MS care. Presented by H.P. Hartung (Germany)
- Understand key prognostic factors for evaluating MS therapy in treatment-naïve patients. Explore the latest insights on biomarkers, imaging, and early clinical indicators that can help optimize treatment selection and predict long-term outcomes. Presented by Magd Zakaria (Egypt)
- Learn how to detect progression in MS through subtle clinical and radiological signs. Gain practical knowledge on using advanced tools to monitor disease activity, disability, and cognitive function over time. Presented by C. Oreja-Guevara (Spain)
- Join an engaging Q&A and panel discussion with leading experts, where you can exchange perspectives, ask questions, and translate the latest evidence into real-world practice. Facilitated by B. Yamout (United Arab Emirates)

With thanks to our sponsor, who supports this Symposium without any involvement in the elaboration of the presentations.

sanofi

For more information visit:



2025.menactrims.org